{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T05:21:20Z","timestamp":1783056080121,"version":"3.54.6"},"reference-count":61,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T00:00:00Z","timestamp":1734912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>The critical role played by vascular dysfunction and ineffective angiogenesis in the pathophysiology of systemic sclerosis (SSc) suggests that circulating biomarkers reflecting these alterations may be useful in the clinical evaluation of this patient group. We sought to address this issue by conducting a systematic review and meta-analysis of studies investigating a such candidate biomarker, endostatin, an endogenous glycoprotein exerting anti-angiogenic effects, in SSc patients and healthy controls.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A literature search was conducted in the electronic databases Web of Science, PubMed, and Scopus from inception to 27 May 2024. Risk of bias and certainty of evidence were assessed using the JBI checklist for analytical studies and GRADE, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In 19 eligible studies, circulating endostatin concentrations were significantly higher in SSc patients than controls (standard mean difference, SMD=0.90, 95% CI 0.56 to 1.23, p&amp;lt;0.001; low certainty of evidence). Endostatin concentrations were also significantly higher in SSc patients with digital ulcers than those without (SMD=0.43, 95% CI 0.24 to 0.62, p&amp;lt;0.001; very low certainty of evidence) and in patients with pulmonary arterial hypertension than those without (SMD=1.21, 95% CI 0.67 to 1.76, p&amp;lt;0.001; very low certainty of evidence). By contrast, no significant differences were observed between SSc patients with limited vs. diffuse disease and those with different video capillaroscopy patterns. There was limited evidence regarding endostatin concentrations in SSc patients with interstitial lung disease, telangiectasias, and gastrointestinal manifestations. There were no significant associations in meta-regression and subgroup analysis of studies investigating endostatin in SSc patients and controls between the effect size and various patient and study characteristics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Therefore, the results of this systematic review and meta-analysis suggest that measuring endostatin can be useful in assessing the presence of SSc and specific complications, i.e., digital ulcers and pulmonary arterial hypertension, in these patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p><jats:uri>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:uri>, identifier CRD42024558174.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2024.1450176","type":"journal-article","created":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T06:42:26Z","timestamp":1734936146000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Endostatin as a biomarker of systemic sclerosis: insights from a systematic review and meta-analysis"],"prefix":"10.3389","volume":"15","author":[{"given":"Arduino A.","family":"Mangoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Zinellu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2010.102","article-title":"Cellular and molecular aspects of vascular dysfunction in systemic sclerosis","volume":"6","author":"Trojanowska","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115282","article-title":"Further insight into systemic sclerosis from the vasculopathy perspective","volume":"166","author":"Ren","year":"2023","journal-title":"BioMed Pharmacother"},{"key":"B3","doi-asserted-by":"publisher","first-page":"15002","DOI":"10.1038\/nrdp.2015.2","article-title":"Systemic sclerosis","volume":"1","author":"Allanore","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01692-0","article-title":"Systemic sclerosis","volume":"401","author":"Volkmann","year":"2023","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/art.37988","article-title":"Review: evidence that systemic sclerosis is a vascular disease","volume":"65","author":"Matucci-Cerinic","year":"2013","journal-title":"Arthritis Rheumatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/life11070610","article-title":"New insights into profibrotic myofibroblast formation in systemic sclerosis: when the vascular wall becomes the enemy","volume":"11","author":"Romano","year":"2021","journal-title":"Life (Basel)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e12440","DOI":"10.1111\/micc.12440","article-title":"Microvascular involvement in systemic sclerosis and systemic lupus erythematosus","volume":"26","author":"Saygin","year":"2019","journal-title":"Microcirculation"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2019.1614915","article-title":"Pathophysiology of systemic sclerosis: current understanding and new insights","volume":"15","author":"Cutolo","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2021.101683","article-title":"Change of the microvascularization in systemic sclerosis, a matter of air","volume":"35","author":"Lemmers","year":"2021","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.2000.01115.x","article-title":"Characterization of autoantibodies to endothelial cells in systemic sclerosis (SSc): association with pulmonary fibrosis","volume":"119","author":"Ihn","year":"2000","journal-title":"Clin Exp Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken279","article-title":"The microvascular endothelium in scleroderma","author":"Kahaleh","year":"2008","journal-title":"Rheumatol (Oxford)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.651013","article-title":"Innate immune modulation induced by EBV lytic infection promotes endothelial cell inflammation and vascular injury in scleroderma","volume":"12","author":"Farina","year":"2021","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199902)42:2<389::AID-ANR23>3.0.CO;2-P","article-title":"Increased serum levels of antibodies against human cytomegalovirus and prevalence of autoantibodies in systemic sclerosis","volume":"42","author":"Neidhart","year":"1999","journal-title":"Arthritis Rheumatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1172\/JCI131700","article-title":"Cytotoxic CD4+ T lymphocytes may induce endothelial cell apoptosis in systemic sclerosis","volume":"130","author":"Maehara","year":"2020","journal-title":"J Clin Invest"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/00002281-199911000-00010","article-title":"Abnormalities of adhesion molecules and chemokines in scleroderma","volume":"11","author":"Sato","year":"1999","journal-title":"Curr Opin Rheumatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203535","article-title":"Vascular endothelial growth factor aggravates fibrosis and vasculopathy in experimental models of systemic sclerosis","volume":"73","author":"Maurer","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"B17","first-page":"37","article-title":"Different contributions of angiostatin and endostatin in angiogenesis impairment in systemic sclerosis: a cohort study","author":"Almeida","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24044097","article-title":"Current trends in vascular biomarkers for systemic sclerosis: A narrative review","volume":"24","author":"Fioretto","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-1833","article-title":"A 27-amino-acid synthetic peptide corresponding to the NH2-terminal zinc-binding domain of endostatin is responsible for its antitumor activity","volume":"65","author":"Tjin Tham Sjin","year":"2005","journal-title":"Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"136ra71","DOI":"10.1126\/scitranslmed.3003421","article-title":"A peptide derived from endostatin ameliorates organ fibrosis","volume":"4","author":"Yamaguchi","year":"2012","journal-title":"Sci Transl Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2021.1983071","article-title":"Endostatin in fibrosis and as a potential candidate of anti-fibrotic therapy","volume":"28","author":"Zhang","year":"2021","journal-title":"Drug Deliv"},{"key":"B22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13075-023-02989-w","article-title":"Proteomic aptamer analysis reveals serum markers that characterize preclinical systemic sclerosis (SSc) patients at risk for progression toward definite SSc","volume":"25","author":"Bellocchi","year":"2023","journal-title":"Arthritis Res Ther"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh156","article-title":"Nailfold videocapillaroscopic patterns and serum autoantibodies in systemic sclerosis","volume":"43","author":"Cutolo","year":"2004","journal-title":"Rheumatol (Oxford)"},{"key":"B24","article-title":"Systematic reviews of etiology and risk","volume-title":"Joanna Briggs Institute Reviewer\u2019s Manual","author":"Moola","year":"2017"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"B30","article-title":"Assessing the influence of a single study in the meta-analysis estimate","volume":"47","author":"Tobias","year":"1999","journal-title":"Stata Tech Bulletin"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/s0895-4356(01)00377-8","article-title":"Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis","volume":"54","author":"Sterne","year":"2001","journal-title":"J Clin Epidemiol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/j.0006-341x.2000.00455.x","article-title":"Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis","volume":"56","author":"Duval","year":"2000","journal-title":"Biometrics"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200004)43:4<889::AID-ANR21>3.0.CO;2-5","article-title":"Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis","volume":"43","author":"Hebbar","year":"2000","journal-title":"Arthritis Rheumatol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"R11","DOI":"10.1186\/ar596","article-title":"Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers","volume":"4","author":"Distler","year":"2002","journal-title":"Arthritis Res"},{"key":"B36","article-title":"Duration of Raynaud's phenomenon is negatively correlated with serum levels of interleukin 10 (IL-10), soluble receptor of interleukin 2 (sIL2R), and sFas in systemic sclerosis patients","volume":"10","author":"Dziankowska-Bartkowiak","year":"2004","journal-title":"Med Sci Monit"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.080516","article-title":"Abnormalities in the regulators of angiogenesis in patients with scleroderma","volume":"36","author":"Hummers","year":"2009","journal-title":"J Rheumatol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.140657","article-title":"Dysbalance of angiogenic and angiostatic mediators in patients with mixed connective tissue disease","volume":"70","author":"Distler","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1186\/ar4217","article-title":"Correlations between angiogenic factors and capillaroscopic patterns in systemic sclerosis","volume":"15","author":"Avouac","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-012-2378-4","article-title":"Circulating angiopoietin and Tie-2 levels in systemic sclerosis","volume":"33","author":"Dunne","year":"2013","journal-title":"Rheumatol Int"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.12130","article-title":"Dysregulation of angiogenic homeostasis in systemic sclerosis","volume":"16","author":"Farouk","year":"2013","journal-title":"Int J Rheum Dis"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0756-5","article-title":"Associations between circulating endostatin levels and vascular organ damage in systemic sclerosis and mixed connective tissue disease: an observational study","volume":"17","author":"Reiseter","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0130166","article-title":"Systemic sclerosis sera impair angiogenic performance of dermal microvascular endothelial cells: therapeutic implications of cyclophosphamide","volume":"10","author":"Ribatti","year":"2015","journal-title":"PLoS One"},{"key":"B44","article-title":"Predictive value of vascular disease biomarkers for digital ulcers in systemic sclerosis patients","volume":"33","author":"Silva","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185x.13196","article-title":"Potential biomarkers in patients with systemic sclerosis","volume":"21","author":"Delle Sedie","year":"2017","journal-title":"Int J Rheumatic Diseases"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1111\/iwj.12882","article-title":"Serum level of endostatin and digital ulcers in systemic sclerosis patients","volume":"15","author":"Gigante","year":"2018","journal-title":"Int Wound J"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1177\/2397198318776593","article-title":"Female sexual dysfunction in systemic sclerosis: The role of endothelial growth factor and endostatin","volume":"4","author":"Gigante","year":"2019","journal-title":"J Scleroderma Relat Disord"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-019-04863-0","article-title":"Vascular biomarkers and digital ulcerations in systemic sclerosis: results from a randomized controlled trial of oral treprostinil (DISTOL-1)","volume":"39","author":"Mecoli","year":"2020","journal-title":"Clin Rheumatol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13075-020-2128-z","article-title":"Detecting gastrointestinal manifestations in patients with systemic sclerosis using anti-gAChR antibodies","volume":"22","author":"Nakane","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02591-2020","article-title":"Identifying early pulmonary arterial hypertension biomarkers in systemic sclerosis: machine learning on proteomics from the DETECT cohort","volume":"57","author":"Bauer","year":"2021","journal-title":"Eur Respir J"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1177\/23971983231175213","article-title":"Nailfold capillaroscopy and candidate-biomarker levels in systemic sclerosis-associated pulmonary hypertension: A cross-sectional study","volume":"8","author":"Lemmers","year":"2023","journal-title":"J Scleroderma Relat Disord"},{"key":"B52","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/1467-8721.ep10768783","article-title":"Statistical power analysis","volume":"1","author":"Cohen","year":"1992","journal-title":"Curr Dir Psychol Sci"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/s0092-8674(00)81848-6","article-title":"Endostatin: an endogenous inhibitor of angiogenesis and tumor growth","volume":"88","author":"O'Reilly","year":"1997","journal-title":"Cell"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M202771200","article-title":"Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR\/Flk-1","volume":"277","author":"Kim","year":"2002","journal-title":"J Biol Chem"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5002040","article-title":"Endostatin peptide, an inhibitor of angiogenesis, prevents the progression of peritoneal sclerosis in a mouse experimental model","volume":"71","author":"Tanabe","year":"2007","journal-title":"Kidney Int"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S191617","article-title":"Endostatin attenuates PDGF-BB- or TGF-beta1-induced HSCs activation via suppressing RhoA\/ROCK1 signal pathways","volume":"13","author":"Ren","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2016.00145","article-title":"Recombinant human endostatin suppresses mouse osteoclast formation by inhibiting the NF-kappaB and MAPKs signaling pathways","volume":"7","author":"Chen","year":"2016","journal-title":"Front Pharmacol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1631\/jzus.B1700052","article-title":"Endostatin inhibits fibrosis by modulating the PDGFR\/ERK signal pathway: an in vitro study","volume":"18","author":"Li","year":"2017","journal-title":"J Zhejiang Univ Sci B"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-016-3219-8","article-title":"Impaired angiogenesis as a feature of digital ulcers in systemic sclerosis","volume":"35","author":"Silva","year":"2016","journal-title":"Clin Rheumatol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.924899","article-title":"Peripheral microangiopathy changes in pulmonary arterial hypertension related to systemic sclerosis: data from a multicenter observational study","volume":"9","author":"Giuggioli","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1177\/2397198319833486","article-title":"Nailfold capillaroscopy in systemic sclerosis - state of the art: The evolving knowledge about capillaroscopic abnormalities in systemic sclerosis","volume":"4","author":"Lambova","year":"2019","journal-title":"J Scleroderma Relat Disord"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1450176\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T06:42:30Z","timestamp":1734936150000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1450176\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,23]]},"references-count":61,"alternative-id":["10.3389\/fimmu.2024.1450176"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1450176","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,23]]},"article-number":"1450176"}}